Background: Whether placental location confers specific neonatal risks is controversial. In particular, whether placenta previa is associated with intra-uterine growth restriction (IUGR)/small for gestational age (SGA) remains a matter of debate.
Introduction
Placenta previa refers to the presence of placental tissue that extends over the internal cervical os during pregnancy [1] . The incidence of this condition is reported to be 2% at 20 weeks of gestation, and through the process of placental migration known as trophotropism, decreases to around 4-6 per 1000 births between 34 and 39 weeks [2] . The primary risk factors for the development of placenta previa include a prior history of placenta previa, previous cesarean delivery, multiple gestations, use of fertility treatments and increasing maternal age, among others [3] . The risk of recurrence in subsequent pregnancies is reported at 4-8% [4] .
Given its location over the cervical os, a proportion of the placental surface is exposed and lacks a proper uteroplacental interphase. Well-established sequelae of this condition include the potential for severe antenatal bleeding and preterm birth, as well as the need for cesarean delivery [3, 5] . The risk of bleeding is thought to occur when uterine contractions or gradual changes in the cervix and lower uterine segment apply shearing forces to the inelastic placental attachment site, resulting in partial detachment.
For this reason, it is theorized that a lower placentaldecidua surface area may confer an increased risk of adverse neonatal outcomes, including neonatal anemia, respiratory distress, hyperbilirubinemia, neonatal intensive care unit (NICU) admission and perinatal death [1] . Though given its pathophysiology of decreased placental surface and inadequate circulation may in theory explain an increased risk of adverse neonatal outcomes, whether the risk of intrauterine growth restriction (IUGR)/small for gestational age (SGA) is increased in placenta previa remains a matter of controversy [6, 7] . In this study, we conducted a systematic review and meta-analysis to determine the risk of IUGR/ SGA in pregnancies complicated by placenta previa relative to those with normal placental insertion sites.
Materials and methods

Sources
We performed a Medline, EMBASE, Google Scholar, Scopus, ISI Web of Science and Cochrane database search, as well as PubMed (www.pubmed.gov) search until the end of December 2018 from the last 30 years using the following Boolean search criteria: "(Placenta previa OR previa) AND (intrauterine growth restriction OR IUGR) OR (fetal growth restriction OR FGR) OR (small for gestational age OR SGA) OR (low birth weight OR LBW)". Other than restricting the search to human studies and to articles in English, other limiting categorical terms used were the restriction to studies with singleton pregnancies and without any evidence of aneuploidy, congenital anomalies or placental trophoblastic invasion (accreta spectrum). The reference lists and bibliographies of included studies were then searched for other salient and pertinent manuscripts. Finally, manual searches of studies belonging to research teams having prior publications on placenta previa and growth restriction were undertaken, and other pertinent studies retrieved. This review was modeled on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, and search flowchart depicting the search strategy is illustrated in Figure 1 . 
Study selection
All authors independently examined the electronic search results for reports of possibly relevant studies and those reports were retrieved and analyzed in further detail. Published studies were eligible for inclusion if they compared the risk of IUGR/SGA between cases of placenta previa and cases of normal placental location. In undertaking our search, we defined IUGR/SGA as birth weight below the 10 th percentile, regardless of the terminology used in individual studies. Indeed, we included studies, which used terminology such as "small for gestational age", "fetal growth restriction" and "low birth weight", provided that they referred to neonates born under the 10 th percentile corrected for gestational age. In addition, we made no distinction between the mode of diagnosis of placenta previa, the placental orientation, the presence of antepartum bleeding, nor the year or country of origin of the study in question.
All studies were assessed following predetermined quality criteria including the presence of a power calculation, the unit of analysis used and risk of bias. Risk of bias was assessed using the Cochrane Handbook for Systematic Reviews of Interventions (results not shown). We attempted to contact one author to obtain supplementary information regarding their study, but did not receive a response. As such, we did not include the study in question into our analysis for lack of complete information.
We used odds ratios (OR) and a fixed effects (FE) model with the Mantel-Haenszel method to calculate weighted estimates and their 95% confidence intervals (CI) where appropriate. A forest plot and a funnel plot are provided for visualization of the results (Figures 2 and 3 ). Statistical heterogeneity between results of studies was examined by inspecting the scatter in the data points on the graphs and the overlap of CIs, and by checking the χ 2 and I 2 statistics. The Review Manager 5.3.5 software (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used to combine data for the meta-analysis. This meta-analysis was exempt from Institutional Review Board (IRB) approval because of the nature of the research design (review article), as well as the lack of use of identified patient data.
Results
We obtained 357 records, of which 13 met the inclusion criteria. All study designs were retrospective in nature, and included 11 cohort and two case-control studies. Study characteristics and individual inclusion criteria are provided in Table 1 . A total of 1,593,226 singleton known fetal/neonatal malformation, cases with concurrent placenta accreta and cases missing data -Control = elective c/s during same period, for malpresentation or previous c/s and placenta sent to pathology Diagnosis of placenta previa confirmed in all women in the third trimester TV US + placenta sent to pathology pregnancies were included, of which 10,575 had a placenta previa. The incidence of growth abnormalities was 8.7/100 births in cases of placenta previa vs. 5.8/100 births among controls. Relative to cases with alternative placental location, pregnancies with placenta previa were associated with a mild increase in the risk of IUGR/ SGA, with a pooled OR (95% CI) of 1.19 (1.10-1.27) (forest plot - Figure 2) . A funnel plot is provided in Figure 2 for visualization of the results. Statistical heterogeneity was high with an I 2 = 94%.
Discussion
The most common presentation of placenta previa is as a finding on routine ultrasound examination at about 16-20 weeks of gestation for assessment of gestational age, fetal anatomic survey or prenatal diagnosis [1, 3] . The diagnosis of placenta previa requires the identification of echogenic homogeneous placental tissue over the internal cervical os [18] . One to six percent of pregnant women are found to have sonographic evidence of a placenta previa on these examinations [19] . When placenta previa persists near term, several important adverse maternal and neonatal outcomes may ensue. However, whether placenta previa increases the risk of IUGR/SGA is controversial. In this meta-analysis of over 1,593,226 singleton pregnancies and 10,575 confirmed cases of placenta previa, we show that placenta previa increases the relative risk of IUGR/SGA by an average of 19% (95% CI 10-27%).
Whether one should consider placenta previa in the same category as other placental insertion abnormalities is unknown. Nevertheless, several clinical associations with other placental conditions exist, which may point to an underlying genetic susceptibility. One hypothesis is that the presence of areas of suboptimally vascularized decidua in the upper uterine cavity due to previous surgery or multiple pregnancies promotes implantation of trophoblast in healthy decidua near the lower uterine cavity [20] .
It is well documented that when placenta previa is diagnosed, the possibility of placenta previa-accreta should be considered [21] . In a prospective study of women with placenta previa undergoing cesarean delivery, the frequency of placenta accreta increased proportionally with an increasing number of cesarean deliveries. Similarly, placenta previa is a known risk factor for vasa previa and velamentous umbilical cord insertion [19, 21] .
Despite the controversial evidence, several theories have attempted to explain the potential etiologies of an association between placenta previa and growth abnormalities in the fetus. First, as the muscle mass and contractile work of the corpus uteri and fundus are greater than in the lower uterine segment, the blood supply to the latter is likely lower, presumably resulting in lower perfusion for a low-lying placenta previa. Similarly, repeated bleeding episodes from placenta previa may impact fetal oxygenation and growth. In keeping with this theory, numerous reports have documented an increased risk of fetal anemia in cases of placenta previa, which may be related both to intra-placental bleeding of fetal origin during pregnancy and to the incision through the fetal vessels in the placenta during cesarean delivery [1] . Finally, whether epidemiologic confounders or modifying variables in certain studies account for an increased risk of IUGR/SGA has been observed. The prime example is the study by Räisänen et al. [11] , which finds an increased risk of IUGR with placenta previa, only among multiparous, but not nulliparous women. That said, differences in the risk of fetal growth restriction have been observed depending on whether univariate or multivariate analyses are undertaken [7, 20, 22, 23] .
Clinical implications of the findings
The management of pregnancies at risk of IUGR includes the provision of prenatal screening, the adequate assessment of fetal anatomy, the continuous monitoring of fetal biometry throughout gestation and, in select cases, the provision of anticoagulation or anti-platelet therapy [24] . As with most normal pregnancies, before a placenta previa is diagnosed, the vast majority of patients will have undergone regular prenatal screening and evaluation of fetal anatomy. Given the need to re-assess placental location and its distance to the internal os in the third trimester to plan for delivery, fetal growth is already likely to be estimated at that time again. Moreover, given the substantial risk of antepartum hemorrhage, whether the provision of aspirin and anticoagulation in women with placenta previa increases such risk has not been studied. Therefore, at the present time, the findings of this study are unlikely to alter the current clinical management of these pregnancies.
That said, once IUGR is established, fetal Doppler studies are recommended to screen for signs of placental insufficiency and fetal distress [24] . Depending on the etiology and severity of IUGR, delivery is likely to be induced around 38-39 weeks of gestation. However, given the risk of catastrophic hemorrhage, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Society for Maternal-Fetal Medicine recommend that pregnancies with uncomplicated placenta previa be delivered between 36 + 0 and 37 + 6 weeks of gestation [25] . Therefore, at the present time, there is no evidence that specifically monitoring fetal growth or Doppler studies with serial ultrasound examinations is useful in cases of placenta previa. Given the findings of this study, which only suggest a mild increase in the risk of IUGR/ SGA, we do not propose that further screening with serial scans be undertaken at this time. Nevertheless, what the findings of this study may in fact prompt is a more comprehensive counseling to patients, as well as to the NICU team, who may care for the neonates with this condition, often born in the late-preterm or early-term period.
Strengths and limitations
The strengths of this study are multiple and include the vast number of patients analyzed, the homogeneity of the inclusion criteria across studies, as well as the use of proper statistical techniques. Similarly, to the best of our knowledge, ours is the first and only meta-analysis in the literature addressing the association between placenta previa and growth restriction, an increasingly important and relevant question in clinical medicine today. On the other hand, the limitations of our study are several and worth mentioning. First, while all of the studies included in the meta-analysis addressed the outcome of IUGR, the definitions are not strictly identical and as such, they may introduce bias into our estimates. Indeed, the literature is notoriously heterogeneous with regard to terminology about growth restriction, with some reports considering growth under the 10 th percentile as diagnostic while others do so in cases under the fifth or third centile. That said, all weight estimates were sonographically determined and the same criteria were used for all patients in each individual study. Likewise, though individual studies may use a different terminology, be it IUGR or SGA, all refer to fetuses whose growth falls below the 10 th percentile for gestational age. Second, though the pooled number of patients is high, statistical heterogeneity between studies was large as well, with an I 2 of 94%. Third, given the retrospective nature of the study designs included in the metaanalysis, adjusting for different confounders in individual studies may have introduced information bias. To mitigate these, we conducted sensitivity analyses looking at univariate and multivariate estimates in individual studies, and our findings and conclusion remained unchanged. Finally, despite the robustness of our findings, we cannot prove a causal relationship between placenta previa and IUGR/SGA.
Conclusion
Neonates from pregnancies with placenta previa have a mild but significant increase in the risk of IUGR/SGA. A greater understanding of placenta previa and its consequences can allow providers to better inform, counsel and manage patients with this condition. Whether the degree of IUGR/SGA is significant and whether it requires increased surveillance and/or prompt delivery are outside the scope of the current study. Future studies should attempt to address this question.
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